Letrozole Tablet, Film Coated
Product Images NDC 24979-726

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 24979-726). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)
Chemical structure of Letrozole showing its molecular framework with connected aromatic rings and functional groups as depicted in the image.*
FDA Label Image

Figure-1 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)

Figure-1 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)
A line graph depicting disease-free survival over time (months) up to 72 months, comparing two treatments: Letrozole and Tamoxifen. The y-axis shows survival probability from 0.0 to 1.0, and the x-axis shows months. Two survival curves are plotted, with Letrozole and Tamoxifen represented by different line styles. Patient numbers at risk are listed at various time points below the x-axis.*
FDA Label Image

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)
A Kaplan-Meier plot showing estimates of time to progression over months for two groups: one receiving Letrozole tablets 2.5 mg and the other tamoxifen 20 mg. The y-axis represents progression-free probability, and the x-axis represents months, illustrating comparative progression rates between the treatments over approximately 60 months.*
FDA Label Image

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)
A survival curve chart titled 'Survival by Randomized Treatment Arm' comparing survival over time in months for two treatment groups: letrozole first and tamoxifen first. The y-axis shows the proportion alive ranging from 0.0 to 1.0, while the x-axis shows time in months up to 60. Two descending curves show survival probability trends for each treatment group.*
FDA Label Image

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)
A Kaplan-Meier survival plot illustrating time to progression in days for treatment groups receiving Letrozole Tablets 0.5 mg, Letrozole Tablets 2.5 mg, and a comparator MA (Megestrol Acetate) group. The graph shows progression probabilities over nearly 1000 days.*
FDA Label Image

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)
A Kaplan-Meier survival curve chart showing estimates of time to progression in days from an aminoglutethimide study. The chart compares different treatment groups, including Letrozole Tablets in 0.5 mg and 2.5 mg dosages and an aminoglutethimide group, illustrating time-dependent progression probabilities.*
FDA Label Image

Image Description (Label 90)

Image Description (Label 90)
Label for Letrozole Tablets, USP 2.5 mg film-coated oral tablets. The label states the product contains 90 tablets and is for prescription use only (Rx only). Manufactured for TWi Pharmaceuticals USA, Inc. and by Bora Pharmaceutical Services Inc. The label includes dosage and storage instructions and notes the presence of FD&C Yellow No. 5 (tartrazine) as a color additive.*
FDA Label Image

Image Description (Label)

Image Description (Label)
Letrozole Tablets USP 2.5 mg film-coated tablets label with dosage, storage instructions, and manufacturer information. The package states Rx only and contains 30 tablets. Labeler is Upsher-Smith Laboratories, LLC, with NDC 24979-726-06. It includes a color additive FD&C Yellow No. 5.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.